Alezzandrini
Hospitals & Physicians Clinics · Argentina · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Av Cordoba, Ciudad Autónoma de Buenos Ai...Phone Number
+54 1148123618Website
www.alezzandrini.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About Alezzandrini
Alezzandrini Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alezzandrini your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Alezzandrini had a recent Job posting/layoffs
Earning: See what the market has to say on Alezzandrini recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Alezzandrini has recently received funding, and reach out quickly before it becomes old news!
Check out if Alezzandrini is spiking on competitors!
Alezzandrini, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Alezzandrini launches new products
Congratulate Masked Content for being promoted to Masked Content at Alezzandrini
Funding: Get notified immidiatlly once Alezzandrini has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Alezzandrini as Masked Content
Find 3 more new buyers
Top Hospitals & Physicians Clinics Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Alezzandrini
Oftalmos, led by Dr. Arturo Alezzandrini, specializes in ophthalmology, offering services such as cataract surgery, refractive surgery, and treatment for various eye conditions including glaucoma and maculopathies. With over 20 years of experience in clinical research, the company conducts safe and ethical trials to evaluate new treatments, aiming... Read More
